Amarin Announces Contractual Reminder of Optional Put to Holders of $15.1 million Principal Amount of Outstanding 3.50% Excha...
December 16 2016 - 4:31PM
Amarin Corporation plc (NASDAQ:AMRN) (the “Company”) announced
today that it is providing a contractual reminder to holders of the
outstanding 3.50% Exchangeable Senior Notes due 2032 (CUSIP Number:
220480 AC1) (the “Notes”) of its wholly owned subsidiary,
Corsicanto Designated Activity Co (f/k/a Corsicanto Limited) (the
“Issuer”), of which approximately $15.1 million principal amount is
outstanding, that they have the right to surrender their Notes for
repurchase by the Issuer pursuant to their existing option (the
“Optional Put”) under the Indenture governing the Notes, dated as
of January 9, 2012. No new option is offered hereunder.
The Optional Put entitles each holder of the
Notes to require the Issuer to purchase all or any part of such
holder’s Notes on January 19, 2017 (the “Repurchase Date”) for cash
at a purchase price (the “Repurchase Price”) equal to 100% of the
principal amount of the Notes, plus accrued and unpaid interest
thereon up to, but excluding, the Repurchase Date.
The opportunity for each holder of the Notes to
exercise the Optional Put commences today at 4:30 p.m., New York
City time, and expires at 11:59 p.m., New York City time, on
Wednesday, January 18, 2017, which is the business day immediately
preceding the Repurchase Date. In order to exercise the Optional
Put and receive the Repurchase Price, or withdraw Notes previously
surrendered, a holder must follow the procedures set forth in the
Optional Put Company Notice, which is being delivered to all
registered holders of the Notes.
None of the Company, the Issuer or the Company’s
board of directors or employees has made or is making any
representation or recommendation as to whether or not any holder
should surrender any Notes.
Additional
Information
At the Issuer’s request, Wells Fargo Bank,
National Association, the Trustee, Paying Agent and Exchange Agent
for the Notes, is delivering an Optional Put Company Notice to all
registered holders of the Notes. In addition, the Company and the
Issuer will file the Optional Put Company Notice with a Tender
Offer Statement on Schedule TO with the Securities and Exchange
Commission today. Copies of the Optional Put Company Notice and
additional information relating to the procedure for the surrender
of the Notes may be obtained from Wells Fargo Bank, National
Association by calling (917) 260-1593.
About Amarin
Amarin Corporation plc is a biopharmaceutical
company focused on the commercialization and development of
therapeutics to improve cardiovascular health. Amarin's product
development program leverages its extensive experience in lipid
science and the potential therapeutic benefits of polyunsaturated
fatty acids. Amarin's clinical program includes a commitment to an
ongoing outcomes study. Vascepa® (icosapent ethyl), Amarin's first
FDA-approved product, is a highly-pure, EPA-only, omega-3 fatty
acid product available by prescription. For more information about
Vascepa, visit www.vascepa.com. For more information about Amarin,
visit www.amarincorp.com.
Availability of Other Information about
Amarin
Investors and others should note that we
communicate with our investors and the public using our company
website (www.amarincorp.com), our investor relations website
(http://www.amarincorp.com/investor-splash.html), including but not
limited to investor presentations and investor FAQs, Securities and
Exchange Commission filings, press releases, public conference
calls and webcasts. The information that we post on these channels
and websites could be deemed to be material information. As a
result, we encourage investors, the media, and others interested in
Amarin to review the information that we post on these channels,
including our investor relations website, on a regular basis. This
list of channels may be updated from time to time on our investor
relations website and may include social media channels. The
contents of our website or these channels, or any other website
that may be accessed from our website or these channels, shall not
be deemed incorporated by reference in any filing under the
Securities Act of 1933 or under the Securities and Exchange Act of
1934.
Amarin contact information
Investor Relations:
Gene Mack
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
investor.relations@amarincorp.com
Lee M. Stern
Trout Group
In U.S.: +1 (646) 378-2922
lstern@troutgroup.com
Media Inquiries:
Kristie Kuhl
Finn Partners
In U.S.: +1 (212) 583-2791
Kristie.kuhl@finnpartners.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024